Trader consensus heavily favors no new COVID variant of concern before 2027 because SARS-CoV-2 has continued evolving primarily through Omicron sublineages without triggering formal VOC criteria from WHO or ECDC. As of mid-2026, no lineages meet the thresholds for substantially increased transmissibility, severity, or immune escape that would warrant that designation, despite ongoing genomic surveillance tracking variants under monitoring such as NB.1.8.1, XFG, BA.3.2, and PQ.16.1.1. Recent data show these strains circulating at stable or declining prevalence with low overall case severity and minimal impact on healthcare systems. The absence of any escalation in the first half of 2026, combined with routine monitoring rather than emergency alerts, supports the strong implied probability that the situation will hold through year-end.